

Supplementary appendix






Figure S1: Matched propensity scoring in the siltuximab-treated (n=30) and control patient (n=30) cohorts







Figure S2: change in a) total white blood cell, b) lymphocyte, c) neutrophil and d) monocyte counts in siltuximab-treated patients




Figure S3: Probability of logarithmic IL-6

Table S1: Baseline patient and disease characteristics for the unmatched patient cohorts (siltuximab-treated patients and all patients in the control cohort)

	Siltuximab-treated patients, IMV n=5	Siltuximab-treated patients, CPAP/NIV n=25	All siltuximab patients n=30	Control n=188
Sex				
Male	4 (80·0%)	19 (76·0%)	23 (76·6%)	141 (75·0%)
Female	1 (20·0%)	6 (24·0%)	7 (23·3%)	46 (24·5%)
Age, years				
Median (IQR)	64 (53–65)	64 (58–69)	64 (57–66)	67 (56–75)
Height, cm				
Median (IQR)	175·0 (170·0–180·0)	175·0 (168·0–180·0)	175·0 (168·0–180·0)	173·0 (167·0–176·5)
Weight, kg				
Median (IQR)	87·0 (70·0–110·0)	83·0 (77·0–91·0)	84·0 (77·0–95·0)	80·0 (75·0–90·5)
Comorbidities				
Hypertension	1 (20·0%)	11 (44·0%)	12 (40·0%)	106 (56·4%)
Diabetes	0	6 (24·0%)	6 (20·0%)	43 (22·9%)
Cardiovascular disease	0	4 (16·0%)	4 (13·3%)	43 (22·9%)
Malignancies	1 (20·0%)	2 (8·0%)	3 (10·0%)	0
Cerebrovascular disease	0	1 (4·0%)	1 (3·3%)	8 (4·3%)
Chronic kidney disease	0	1 (4·0%)	1 (3·3%)	12 (6·4%)
Medications at baseline				
Antiplatelet therapy	0	4 (16·0%)	4 (13·3%)	46 (24·5%)
ACE inhibitors	0	2 (8·0%)	2 (6·7%)	32 (17·0%)
Angiotensin receptor blocker	1 (20·0%)	8 (32·0%)	9 (30·0%)	36 (19·1%)
Home use of oxygen	0	0	0	3 (1·6%)
Anti-hypertensive therapy	1 (20·0%)	8 (32·0%)	9 (30·0%)	76 (40·4%)
Inhaler	0	0	0	11 (5·9%)
Insulin	0	1 (4·0%)	1 (3·3%)	19 (10·1%)
Oral anticoagulants	0	0	0	20 (10·6%)

Oral antidiabetics	0	5 (20·0%)	5 (16·7%)	29 (15·4%)
Proton pump inhibitor	0	0	0	50 (26·6%)
Steroids	0	0	0	10 (5·3%)
Signs and symptoms				
Fever	4 (80·0%)	22 (88·0%)	26 (86·7%)	169 (89·9%)
Dry cough	2 (40·0%)	14 (56·0%)	16 (53·3%)	91 (48·4%)
Diarrhoea	0	5 (20·0%)	5 (16·7%)	7 (3·7%)
Fatigue	2 (40·0%)	5 (20·0%)	7 (23·3%)	46 (24·5%)
Myalgia	0	4 (16·0%)	4 (13·3%)	6 (3·2%)
Anorexia	0	2 (8·0%)	2 (6·7%)	8 (4·3%)
Respiratory support upon enrolment				
Invasive ventilation	1 (20·0%)	0	1 (3·3%)	19 (9·0%)
Continuous positive airway pressure/non-invasive ventilation	4 (80·0%)	25 (100·0%)	29 (96·7%)	171 (91·0%)
Time to start of ventilation from hospitalisation, days				
Median (IQR)	3 (3–3)	2 (1–3)	2 (1–3)	2 (1–4)
	Siltuximab-treated patients, IMV n=5	Siltuximab-treated patients, NIV n=25	All siltuximab patients n=30	Control n=156
PP arterial O₂ /fraction inspired O₂				
Median (IQR)	96·00 (95·00–96·00)	132·00 (92·86–154·00)	109·17 (92·86–153·00)	196·00 (103·50–252·00)

IQR=interquartile range.

Table S2: Siltuximab administration

	Siltuximab-treated patients, IMV n=5	Siltuximab-treated patients, CPAP/NIV n=25	All siltuximab patients n=30
--	--	--	--

First dose received, mg/kg			
Median (IQR)	10·83 (10·71–10·91)	11·04 (10·91–11·43)	10·99 (10·83–11·32)
First dose			
≥11·5 mg/kg	5 (100%)	7 (28%)	12 (40%)
Patients receiving second dose		6 (24%)	6 (20%)

IQR=interquartile range.